PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Hiromichi Ebi,Carlotta Costa,Anthony C. Faber,Madhuri Nishtala,Hiroshi Kotani,Dejan Juric,Patricia Della Pelle,Youngchul Song,Seiji Yano,Mari Mino-Kenudson,Cyril H. Benes,Jeffrey A. Engelman
DOI: https://doi.org/10.1073/pnas.1314124110
IF: 11.1
2013-12-10
Proceedings of the National Academy of Sciences
Abstract:Significance Genetic alterations targeting the PI3K pathway are highly prevalent in breast cancers. Although breast cancers harboring PIK3CA mutation and HER2 amplification have enhanced sensitivity to PI3K inhibitors, the mechanism underlying this sensitivity is unknown. This study shows that PI3K inhibitors suppress MEK/ERK pathway in these cancers, and inhibition of both AKT and ERK pathways is necessary for maximal antitumoral activity. We elucidate a unique mechanistic link between PI3K and ERK via PI3K-dependent regulation of P-Rex1, which in turn regulates the Rac1/PAK/c-RAF/MEK/ERK pathway. Importantly, expression levels of the Rac-GEF, P-Rex1, correlate with sensitivity to PI3K inhibitors among these breast cancer cell lines, indicating its potential utility as a biomarker to identify cancers that will respond to PI3K inhibitors.
What problem does this paper attempt to address?